EF-14
The trial that made a wearable electric-field device part of glioblastoma care, extending median survival by about five months.
695 patients, open-label. Median OS 20.9 vs 16.0 months (HR 0.63); 5-year OS 13% vs 5%. Stopped early for efficacy at interim analysis. Benefit correlated with device usage. Debated for lack of a sham control; NCCN category 1.
- Median 6.7 vs 4 months with TTFields + temozolomide compared with Temozolomide; about 2.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63, likely range 0.52 to 0.76).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 20.9 vs 16 months with TTFields + temozolomide compared with Temozolomide; about 4.9 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63, likely range 0.53 to 0.76).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Newly diagnosed glioblastoma after chemoradiation: TTFields + maintenance temozolomide vs temozolomide alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
695 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | TTFields + temozolomide | 466 | 6.7 months | 0.63 (0.52–0.76) | <0.001 | link |
| Temozolomide | 229 | 4 months | ||||
| Overall survival | TTFields + temozolomide | — | 20.9 months | 0.63 (0.53–0.76) | — | link |
| Temozolomide | — | 16 months |
Pages like this
not linked directly; found by shared links- InstitutionRobert H. Lurie Comprehensive Cancer Center of Northwestern University
Shares Novocure, Roger Stupp, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- TrialPANOVA-3
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- TrialEORTC 26981 / NCIC CE.3 (Stupp trial)
Shares Roger Stupp, Temozolomide, The brain: barrier and sanctuary, Glioma & glioblastoma.
- TrialSTELLAR
Shares Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- InstitutionUniversity Hospital Zurich / Comprehensive Cancer Center Zurich
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields), Glioma & glioblastoma.
- Key paperStupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma
Shares Roger Stupp, Tumour treating fields (TTFields), The brain: barrier and sanctuary, Glioma & glioblastoma.
- IdeaRobot-placed catheters and live imaging for drug infusion into brain tumours
Shares Roger Stupp, The brain: barrier and sanctuary, Glioma & glioblastoma.
- IdeaA skull ultrasound implant that opens the barrier at every cycle
Shares Temozolomide, The brain: barrier and sanctuary, Glioma & glioblastoma.